IfLS Research Collaboration Stimulus Fund

Information Session

6 September 2018
AGENDA

• Introduction and call overview – Professor Peter JS Smith, IfLS Director
• Introduction to IfLS Entrepreneur in Residence – James Otter
• Overview: Research Funding support – Linda Hammond, Research Funding Manager
• Overview: Translational Funding support
  - David Woolley and/or James Hamilton, Technology Transfer Managers
  - Phil Jewell, Programme Officer
  - Ruth Saw, Impact Funding Manager

IfLS team on hand to answer any questions on application process
IfLS MEMBERSHIP

By Faculty & Academic Unit

Clinical & Experimental Science
Cancer Sciences
Development
Biological Sciences

Collaborative applications for funding 2015-2017

Faculties:
- FBL (>1%) Business & Law
- FEE (13%) Engineering & Environment
- FHS (7%) Health Sciences
- FH (1%) Humanities
- FM (34%) Medicine
- FNES (28%) Natural & Environmental Sciences
- FPSE (9%) Physical Sciences & Engineering
- FSHMS (8%) Social & Human Sciences
LIFE SCIENCES THEMES

Health and Medicine  Living Systems  Disruptive Life Technologies  Data Insights
INSTITUTE FOR LIFE SCIENCES
RESEARCH COLLABORATION STIMULUS FUND

• Research England awards money to University from the Higher Education Innovation Fund (HEIF)
• Goal to support Knowledge Exchange by working with business
• University and Institute for Life Sciences required to follow an investment strategy
UNIVERSITY KNOWLEDGE EXCHANGE STRATEGY

• Growing and diversifying research collaborations with commercial organisations of all sizes
• Broadening the pool of staff and students engaged in knowledge exchange
• Sustaining and expanding our vibrant enterprise ecosystem
• Ensuring that our enterprise ecosystem has a major impact on the economic contribution to the region, the nation, and the world
• Enhancing engagement for social and economic impact
CALL OVERVIEW

• Facilitate research collaborations with non-academic partners
• Pump-priming projects typically in range £5K - £20K
• Interdisciplinary, disruptive life sciences research
• Must be led by a Principal Investigator who is a Member of IfLS
• Non-academic partner must make meaningful contribution
• Funds must be spent by 31 July 2019
• Interim report due 28 February 2019 – including 4 page outline grant proposal with non-academic partner
• Final report due 31 July 2019 – including a mature grant application or contract proposals with the non-academic partner
TIMELINE

• 12 September – Entrepreneur in Residence advice sessions available – contact a.mant@soton.ac.uk for a slot
• 24 September 17:00 – Application deadline to IfLSAdmin@soton.ac.uk
• October – peer review by IfLS Members
• 24/25 October – panel review session
• End October – applicants notified of outcomes and successful projects commence
• 28 February 2019 – Interim report for IfLS Director, submit to IfLSAdmin@soton.ac.uk
• 31 July 2019 – Complete spend and submit final report and grant/contract proposal to IfLS Director, IfLSAdmin@soton.ac.uk
YOUR QUESTIONS
Research Funding Development Overview and Translation Funding Schemes

Linda Hammond
Research Funding Development
Research and Innovation Services
Research Funding Development Team

• Purpose: Provides expert funding advice and bid management support for large-scale research initiatives, fellowships and first grants.

• Key Activities
  – build strategic relationships with key funders
  – project manage, prioritise and support the submission of key strategic bids
  – support the development of first grants and fellowships and the submission of small grants for new academics and early career researchers
  – provision of resources to support researchers applying for research funding e.g. RFD Self Service portal

• Location: 2nd floor, B28, Highfield

• Contact: funding@soton.ac.uk
Translation Funding Schemes

- Wellcome Trust Innovator Award
- MRC Biomedical Catalyst: Developmental Pathway (DPFS)
- NIHR Invention for Innovation (i4i)
- Other opportunities
Wellcome Trust Innovator Award

• Aim is to develop healthcare innovations that could have a major and measurable impact on human health.

• Researchers can work in any scientific discipline on any type of technology. For multi-disciplinary bids, at least two different disciplines must be involved and one should be from engineering, physical sciences or data science.

• Funding: up to 500K or 750K for multidisciplinary collaborations. PI, large equipment and overhead costs not covered.

• Duration: 2yrs (3yrs for multidisciplinary projects)

• Collaborations: Industry and multidisciplinary collaborations are encouraged

• Deadline : Applications can be made at any time
Biomedical Catalyst: Developmental Pathway (DPFS)

• Aim is to fund the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics

• Eligibility:
  – All disease areas (including those relevant to global health) and modalities of intervention are eligible.
  – Projects can start and finish at any point on the translational pathway.

• Two stage process.

• Funding: No limit

• Collaborations: Industrial collaboration is encouraged but not a prerequisite

• Deadline: Ongoing scheme with deadlines every 4 months

• Applications should be completed in partnership with the lead academic research organisation’s Technology Transfer Office (TTO)
NIHR Invention for Innovation (i4i)

- The scheme covers research and development of medical devices, active implantable devices, in vitro diagnostic devices and product development required to enable a technology for clinical use.

- Projects must have demonstrated ‘proof of principle’ and have a clear pathway towards clinical adoption and commercialisation.

- Collaborations: Involvement of SMEs is welcomed.

- Two funding streams: - Challenge Awards and Product Development Awards

  - Challenge Awards –
    - commissioned on an ad hoc basis in areas of healthcare need. Applications for these awards must be based on a working prototype or proven concept with a strong evidence base, requiring minimal preclinical development.
    - Funding is awarded on a ’winner takes all’ basis.
    - Maximum duration: 5 years
NIHR Invention for Innovation (i4i)

Product Development Awards –

- Supports any stage of the translational research and development pathway, including the clinical development of laboratory-validated technologies or interventions.

- Eligibility:
  - A minimum of two organisations must be involved from either NHS Trust, HEI or SME.

- Funding: No limit

- Duration: Maximum 3 years
Other opportunities

A number of charities support translational research as part of their funding strategy.

Examples include:

- Cancer Research UK
- British Heart Foundation - Translational Award
- Arthritis Research UK - Translational Award
Today’s Presentation....

- Will give you introduction to and awareness of variety of ‘translational’ research schemes / activities
- Initial Guidance on qualifying if you have a relevant opportunity
- Contacts/ sources of information/ what to do next.....
- Later - a chance to ask questions
What is Translational Research?

- Pre-commercial research which:
  - Explores research findings in an application context
  - Investigates parameters relevant to practical (commercial) utility
- Medical context – evaluation & exploration of research findings in early clinical / pre-clinical context.

- Universities can excel at:
  - Rigour & breadth of approach (& ambition/ complexity)

- Universities can fail at:
  - Lack of relevance and focus on deliverables

- Translational research bridges the development gap
This pathway covers the full range of interventions - pharmaceuticals, biologicals, biotechnologies, procedures, therapies and practices - for the full range of health and healthcare delivery - prevention, detection, diagnosis, prognosis, treatment, care.
Principal Approaches for Universities

- Work with and Funded by a Company
- Translational Research Funding
Formal Translational Research Schemes

• Exist amongst a variety of ‘collaborative’ schemes

• These schemes help to progress new discoveries towards commercial development environment

• Many traditional research funders have developed specialist departments/ schemes

• Requires tighter focus on targets to be achieved....

• Definitely not just another grant......
Variety of Schemes

• **Research Councils** –
  - EPSRC, NERC, BBSRC, STFC Follow On Funds
  - Now mainly Impact Acceleration Scheme formats
  - focussed on adding value to potential IP (for further collaboration/ licensing)......

• MRC slightly different - MRC Development Pathway Scheme (*over to James*)
MRC Scheme

DPFS is an ongoing scheme, with outline deadlines every 4 months. The scheme supports the translation of fundamental discoveries toward benefits to human health. It funds the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, including “repurposing” of existing therapies.

The following activities are eligible for support:

- Developing candidate therapeutic entities (e.g. drug discovery)
- Pre-clinical testing of novel therapeutic entities
• Early-phase clinical studies of novel therapeutic entities (phases 1 and 2)

• “Repurposing” clinical studies – using existing therapies for new indications

• Developing and testing novel devices

• Developing and testing diagnostics (including biomarker validation)

• All disease areas (including those relevant to global health) and modalities of intervention are eligible for support from the scheme, including small molecules, peptides, antibodies, vaccines, cell and gene therapy, devices, surgical techniques and psychological approaches.
Wide Variety of Schemes

• Department of Health..... NIHR (i4i programme, Research for Patient Benefit (RfPB), ....)

• Wellcome Trust — Translational Awards, Strategic Translational Awards, etc... good description on website..

• Cancer Research UK — Translational Research Funding

• British Heart Foundation — Translational Scheme

• Royal Society
  – Brian Mercer Innovation & Feasibility Awards (closes Jan annually)
  – Industry Fellowships

• Royal Academy of Engineering (RAEng) Enterprise Fellowships
Do Consider Collaboration /KT – type schemes

- Technology Strategy Board – investment for areas of strategic science/technical importance (Innovation Platforms), collaborative R&D and support for innovative ideas (SBRI)
- Regional Development Agency (e.g. SEEDA, Welsh Assembly, etc....)
- Knowledge transfer vs. IP transferring
  - KTP
  - KTS
  - Industrial CASE PhD Studentship/ other sponsored research
Overview

- Funding to collaborate with Industry
- Translational funding schemes
- Knowledge transfer (KT) schemes
- Studentships (*perhaps*)
What To Do Next........
Tips for What to Think About

• IP position clear and understood

• Only consider this when real commercial interest (R&IS & senior colleagues can help assess this)

• Read available scheme information – generally harder to ensure that fits application criteria
Tips for What to Think About

• R&IS rule of thumb is industry ‘connectivity’/ level of expressed interest is critical to how good an ‘opportunity’
• Talk to R&IS/ tech transfer office – support is usually mandatory
• Be very clear on what you are trying to achieve and what will happen next
  – Do NOT try to do too much; keep it simple/ focused
  – Spend as much time on what you’re going to do next/ options on completion (Impact)
Knowledge Transfer Partnerships
What is a Partnership?

- Relationship formed between:
  - Public Sector body, Company or Charity (‘Company’)  
  - Academic institution (‘Knowledge Base’ Partner)

- Facilitates the transfer of:
  - Knowledge  
  - Technology  
  - Skills  
  
  *to which the company partner currently has no access*

- Each partnership employs one or more recently qualified people (Associate) to work in the ‘Company’ on a project of **strategic importance** to the business, jointly supervised by the Academic Institution and the ‘Company’
Features

- Project length 12 – 36 months
- Increased Innovate UK national budget for KTP
- Deadlines every two months, 100% success rate
- Associates employed by University partner, located c.90% at company premises in the UK
- Academic Supervisor spends around half a day per week at company premises
- Costs to companies
  - SMEs pay ~33% of costs (minimum £23,000 pa)
  - Large companies pay ~50% of costs (minimum £34,000 pa)
KTP Further info

Web address:

www.southampton.ac.uk/business/collaboration/knowledge-transfer-partnerships.page

www.ktponline.org.uk

RIS contact
Phil Jewell  pej@soton.ac.uk  02380 598568
Impact from research can be defined “as an effect on, change or benefit to the economy, society, culture, public policy or services, health, the environment or quality of life, beyond academia” (Research Excellence Framework (2011)).

- IAAs allow us to respond to knowledge exchange opportunities in more flexible, responsive and creative ways
  - Secondments (In or Out)
  - Engagement opportunities/events
  - Develop research findings to the next level (eg prototypes)
  - Relationship development (workshops, user/stakeholders events)

- IAAs enable Southampton to provide funding for knowledge exchange (KE) activities in ways that best suit our institutional strategies and opportunities

- The Impact Acceleration Account (IAA) funds the development of research, rather than funding the research itself.
Impact Acceleration Accounts

Impact funding opportunities at Southampton

• EPSRC
• ESRC
• STFC
• MRC (Confidence in Concept)

*Schemes have different remit/criteria – check guidance carefully*

• Programme of calls being drawn up (including joint calls)
• Information to be made available on Researcher Portal in due course